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lisBACKGROUND The efﬁcacy of direct oral anticoagulants (DOACs) for stroke prevention in patients with atrial ﬁbril-
lation (AF) has been established in clinical trials. However, well-conducted, prospective, real-world observational studies
of the safety and effectiveness of DOACs are needed.
OBJECTIVES This study sought to assess the real-world safety proﬁle of rivaroxaban through a pooled analysis of
patients with AF enrolled in the XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) program
worldwide.
METHODS A pre-planned pooled analysis of the XANTUS, XANAP (Xarelto for Prevention of Stroke in Patients With
Atrial Fibrillation in Asia), and XANTUS-EL (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latin
America and EMEA Region) registries was performed. Patients with AF newly starting rivaroxaban for stroke prevention
were followed for 1 year. Primary outcomes were treatment-emergent major bleeding, adverse events (AEs)/serious AEs,
and all-cause death. Secondary outcomes included treatment-emergent thromboembolic events and nonmajor bleeding.
Major outcomes were centrally adjudicated.
RESULTS Overall, 11,121 patients were included (mean age 70.5  10.5 years; female 42.9%). Comorbidities included
heart failure (21.2%), hypertension (76.2%), and diabetes (22.3%). Event rates were: events/100 patient-years: major
bleeding 1.7 (95% conﬁdence interval [CI]: 1.5 to 2.0; lowest: Latin America 0.7; highest: Western Europe, Canada, and
Israel 2.3); all-cause death 1.9 (95% CI: 1.6 to 2.2; lowest: Eastern Europe 1.5; highest: Latin America, Middle East,
and Africa 2.7); and stroke or systemic embolism 1.0 (95% CI: 0.8 to 1.2; lowest: Latin America 0; highest: East Asia 1.8).
One-year treatment persistence was 77.4% (lowest: East Asia 66.4%; highest: Eastern Europe 84.4%).
CONCLUSIONS This large, prospective, real-world analysis in 11,121 patients from 47 countries showed low bleeding
and stroke rates in rivaroxaban-treated patients with AF, with low treatment discontinuation in different regions of the
world. Results were broadly consistent across regions. (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
[XANTUS]; NCT01606995; Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latin America and
EMEA Region [XANTUS-EL]; NCT01800006; and Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
in Asia [XANAP]; NCT01750788) (J Am Coll Cardiol 2018;72:141–53) © 2018 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2018.04.058
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AE = adverse event
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DOAC = direct oral
anticoagulant
ICH = intracranial hemorrhage
ISTH = International Society on
Thrombosis and Haemostasis
MI = myocardial infarction
o.d. = once daily
SAE = serious adverse event
SE = systemic embolism
TIA = transient ischemic attack
VKA = vitamin K antagonist
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142A trial ﬁbrillation (AF) is estimated toaffect 33.5 million patients world-wide (1). Although often asymptom-
atic, AF is associated with a major disease
burden, including stroke, cardiovascular
death, and heart failure, as well as un-
planned hospitalizations, which often have
cardiovascular causes (2,3). Use of appro-
priate anticoagulation can greatly reduce
the risk of ischemic stroke in patients with
AF (4,5), with options including vitamin K
antagonists (VKAs) and the direct oral anti-
coagulants (DOACs) (apixaban, dabigatran,
edoxaban, and rivaroxaban). On the basis of
the results of large phase III trials that
demonstrated the favorable beneﬁt–risk pro-
ﬁle of DOACs over VKAs (5–9), various guide-
lines recommend DOACs as an alternative, or
in preference to, VKAs (10,11). DOACs areincreasingly used for stroke prevention in patients
with AF (12). Real-world evidence complements the
results from phase III trials and is important for
assessing the safety and effectiveness of approved
medications and in obtaining information on patterns
of use in routine clinical practice (13).SEE PAGE 154The XANTUS program provides a unique source of
real-world data on the use of rivaroxaban for stroke
prevention in patients with AF. The XANTUS program
included 3 prospective studies conducted in 47
countries from different regions of the world,
providing a broad spectrum of global data. Patients
were enrolled from Western and Eastern Europe,
Canada, and Israel in the XANTUS (Xarelto for Pre-
vention of Stroke in Patients With Atrial Fibrillation)
study, the Asia-Paciﬁc region in the XANAP (Xarelto
for Prevention of Stroke in Patients With Atrial
Fibrillation in Asia) study, and Eastern Europe, the
Middle East, Africa, and Latin America in theAtrial Fibrillation WO 2016012783). Dr. Radaideh has received con
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received November 20, 2017; revised manuscript received AprilXANTUS-EL (Xarelto for Prevention of Stroke in Pa-
tients With Atrial Fibrillation in Latin America and
EMEA Region) study (14,15). The purpose of this
pooled analysis of the XANTUS, XANAP, and
XANTUS-EL studies was to assess the global safety
proﬁle of rivaroxaban in routine clinical practice.
METHODS
We performed a pre-planned pooled analysis of the
studies in the XANTUS program (the XANTUS, XANAP,
and XANTUS-EL studies). Detailed methods have been
described previously (14,15). The XANTUS, XANAP,
and XANTUS-EL studies were international, prospec-
tive, observational, noninterventional cohort studies
in consenting adult patients ($18 years of age) with AF
initiating rivaroxaban for the prevention of stroke or
non-central nervous system (non-CNS) systemic em-
bolism (SE). Patients were prescribed rivaroxaban in
accordance with country-speciﬁc drug approvals. The
label-recommended dose is rivaroxaban 20 mg once
daily (o.d.) in patients with creatinine clearance
(CrCl) $50 ml/min and 15 mg o.d. in patients
with CrCl <50 ml/min in all included countries
except Taiwan, where either rivaroxaban 15 mg o.d. or
20 mg o.d. can be prescribed for patients with CrCl
>50 ml/min and either 10 mg o.d. or 15 mg o.d. can be
prescribed for patients with CrCl 15 to 50 ml/min
(16,17). In order to limit selection bias, participating
investigatorswere asked to enroll consecutive patients
by screening and documenting patients with a diag-
nosis of AF in an anonymous patient log ﬁle. The
screening documentation was completed before
eligible, consenting patients signed an informed con-
sent form, and it was not permitted for patient-related
data to be collected from the remaining ineligible or
nonconsenting patients.
Patients were enrolled from 47 countries across 5
regions of the world (Western Europe/Canada/Israel:
Austria, Belgium, Canada, Denmark, France,
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FIGURE 1 Overview of the XANTUS Pooled Analysis
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(A) Patient disposition in the XANTUS pooled analysis. (B) Countries involved in the 3 studies that make up the XANTUS program. *Reasons for not continuing in the
study included, but were not limited to, patient decision and administrative and medical reasons; some patients could have >1 reason for exclusion. XANAP ¼ Xarelto
for Prevention of Stroke in Patients With Atrial Fibrillation in Asia; XANTUS ¼ Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation; XANTUS-EL ¼ Xarelto
for Prevention of Stroke in Patients With Atrial Fibrillation in Latin America and EMEA Region.
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TABLE 1 Baseline Demographics and Patient Characteristics of
Patients Enrolled in the Worldwide XANTUS Program (N ¼ 11,121)
Age, yrs 70.5  10.5
<65 2,884 (25.9)
65 to 75 4,372 (39.3)
>75 3,865 (34.8)
Male 6,354 (57.1)
First available weight, kg 80.0  17.8
BMI, kg/m2 28.0  5.2
BMI >30 kg/m2 2,523 (22.7)
First available creatinine clearance, ml/min
<15 47 (0.4)
$15 to <30 166 (1.5)
$30 to <50 1,061 (9.5)
$50 to #80 3,478 (31.3)
>80 2,320 (20.9)
Missing 4,049 (36.4)
Pre-existing comorbidities
Hypertension 8,476 (76.2)
Diabetes mellitus 2,484 (22.3)
Prior stroke/TIA/non-CNS SE 2,372 (21.3)
Congestive HF 2,359 (21.2)
Prior MI 994 (8.9)
Hospitalization at baseline 2,072 (18.6)
Type of AF
First diagnosed 2,049 (18.4)
Paroxysmal 4,147 (37.3)
Persistent 1,798 (16.2)
Permanent 3,084 (27.7)
Missing 43 (0.4)
CHADS2 score 2.0  1.3
CHADS2 score
0 1,016 (9.1)
1 3,199 (28.8)
2 3,351 (30.1)
3 1,956 (17.6)
4 1,140 (10.3)
5 401 (3.6)
6 58 (0.5)
Missing 0
CHA2DS2-VASc score 3.5  1.7
CHA2DS2-VASc score
0 301 (2.7)
1 1,045 (9.4)
2 2,026 (18.2)
3 2,527 (22.7)
4 2,305 (20.7)
5 1,446 (13.0)
6–9 1,468 (13.2)
Missing 3 (<0.05)
HAS-BLED score 2.0  1.1
HAS-BLED score
0 742 (6.7)
1 3,051 (27.4)
2 4,293 (38.6)
$3 3,016 (27.1)
Missing 19 (0.2)
Continued in the next column
TABLE 1 Continued
Prior antithrombotic therapy
Yes 7,583 (68.2)
No 3,538 (31.8)
Type of prior antithrombotic therapy
VKA 4,119 (37.0)
DTI 427 (3.8)
ASA (excluding DAPT) 2,004 (18.0)
DAPT 115 (1.0)
Factor Xa inhibitor (excluding rivaroxaban) 17 (0.2)
Heparin 264 (2.4)
Other antithrombotic agents 80 (0.7)
Multiple 557 (5.0)
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; ASA ¼ acetylsalicylic acid; BMI ¼ body mass index;
CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes melli-
tus, prior stroke or transient ischemic attack; CHA2DS2 -VASc ¼ congestive heart
failure, hypertension, age $75 years, diabetes mellitus, prior stroke, transient
ischemic attack, or thromboembolism, vascular disease, age 65–74 years, sex
category (female); CNS ¼ central nervous system; DAPT ¼ dual antiplatelet
therapy; DTI ¼ direct thrombin inhibitor; HAS-BLED ¼ hypertension, abnormal
renal or liver function, stroke, bleeding, labile international normalized ratio,
elderly, drugs or alcohol; HF ¼ heart failure; MI ¼ myocardial infarction;
SD ¼ standard deviation; SE ¼ systemic embolism; TIA ¼ transient ischemic attack;
VKA ¼ vitamin K antagonist.
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144Portugal, Sweden, and the United Kingdom; Eastern
Europe: Azerbaijan, the Czech Republic, Georgia,
Hungary, Kazakhstan, Moldova, Poland, Russia,
Slovakia, Slovenia, and Ukraine; the Middle East/Af-
rica: Bahrain, Egypt, Jordan, Kenya, Lebanon,
Pakistan, Saudi Arabia, and the United Arab Emirates;
East Asia: Hong Kong, Indonesia, Malaysia, the
Philippines, Singapore, South Korea, Taiwan,
Thailand, and Vietnam; and Latin America: Argentina,
Chile, Colombia,Mexico, Uruguay, and Venezuela). All
patients were followed up for 1 year, or for $30 days
after permanent discontinuation of rivaroxaban (if <1
year); investigators were asked to collect data at
approximately 3-month intervals. Differences in the
timing of regulatory approval between countries
meant that the studies were completed in subsets of
global regions.
Primary outcomes were related to the safety of
rivaroxaban and recorded as treatment-emergent
adverse events (AEs) or serious adverse events
(SAEs). They included major bleeding events (using
the International Society on Thrombosis and Haemo-
stasis [ISTH] deﬁnition), all-cause death, and any
other AEs and SAEs. Events were considered
treatment-emergent if they occurred from the day of
the ﬁrst dose of rivaroxaban, and up to 2 days after the
last dose in the event of permanent discontinuation of
rivaroxaban. Secondary outcomes included symp-
tomatic thromboembolic events, nonmajor bleeding,
FIGURE 2 Initial Daily Dose of Rivaroxaban by Region
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Other rivaroxaban doses included doses <10 mg o.d. and >20 mg o.d., and were received by 0.10% in Western Europe/Canada/Israel; 0.04%
in Eastern Europe; 0% in the Middle East and Africa; 0.54% in East Asia; and 0% in Latin America. Only 3 patients, all from Western Europe/
Canada/Israel (0.1%), had missing dosing information. o.d. ¼ once daily.
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145treatment satisfaction, treatment persistence, and
reasons for treatment interruption. Treatment satis-
faction was assessed using standardized patient
questionnaires (Anti-Clot Treatment Scale) in selected
countries and additionally by the physician at the ﬁnal
visit. Hemorrhagic strokes were reported as both
stroke and major bleeding events. All major outcomes
(including major bleeding, stroke, SE, transient
ischemic attack [TIA], myocardial infarction [MI], and
all-cause death) were reviewed and adjudicated by a
central adjudication committee, which had access to
all patient data. Statistical analyses, performed on the
full safety population, were exploratory and included
a descriptive analysis of the primary and secondary
outcome variables.
RESULTS
PATIENT POPULATION. In total, 16,187 patients were
screened between June 2012 and December 2014, and
11,122 of these patients were enrolled from 554 centers
worldwide (311, 111, and 132 centers for the XANTUS,
XANAP, and XANTUS-EL studies, respectively); 1patient did not receive rivaroxaban and was excluded
from this analysis (Figure 1). A total of 5,287 (47.5%)
patients were included in the safety analysis from
Western Europe/Canada/Israel, 2,577 (23.2%) from
Eastern Europe, 2,233 (20.1%) from East Asia, 690
(6.2%) from the Middle East/Africa, and 334 (3.0%)
from Latin America. Israel was grouped with Western
Europe and Canada on the basis of a similar health care
system. Baseline demographics and clinical charac-
teristics are summarized in Table 1. Mean patient age
was 70.5 years, and 57.1% of patients were male.
Comorbidities associated with stroke and/or bleeding
events were common and included congestive heart
failure (21.2%), hypertension (76.2%), diabetes melli-
tus (22.3%), and prior stroke/non-CNS SE/TIA (21.3%).
The mean CHADS2 (congestive heart failure, hyper-
tension, age $75 years, diabetes mellitus, prior stroke
or transient ischemic attack) and CHA2DS2-VASc
(congestive heart failure, hypertension, age$75 years,
diabetes mellitus, prior stroke, transient ischemic
attack, or thromboembolism, vascular disease, age 65–
74 years, sex category [female]) scores were 2.0 and
3.5, respectively. In total, 31.8% of patients were
CENTRAL ILLUSTRATION Safety of Rivaroxaban: Cumulative Rates
Major bleeding 11,121 10,720 10,394 10,138 9,823 9,618 9,439 9,239 9,091 8,917 8,703 8,313 6,734 1,862 844 
Stroke/non-CNS SE 11,121 10,729 10,404 10,155 9,842 9,637 9,456 9,257 9,108 8,939 8,724 8,332 6,748 1,864 843 
Death 11,121 10,726 10,403 10,153 9,847 9,646 9,471 9,272 9,125 8,961 8,751 8,351 6,772 1,871 845 
0.030
0.025
0.020
0.015
0.010
0.005
0.000
4203903603303002702402101801501209060300
Time to Event (Days)
Cu
m
ul
at
iv
e 
Ev
en
t R
at
e
Death Major Bleeding Stroke/Non-Central Nervous 
System Systemic Embolism (CNS SE) 
Kirchhof, P. et al. J Am Coll Cardiol. 2018;72(2):141–53.
Kaplan-Meier curves for treatment-emergent all-cause death, major bleeding events, and stroke/non-CNS SE.
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146anticoagulation- or antiplatelet therapy-naive at
baseline; 37.0% of patients previously received a VKA;
4.0% received a direct thrombin inhibitor or Factor Xa
inhibitor; and 18.0% received acetylsalicylic acid.
Of 11,121 patients who completed the study,
8,540 patients (76.8%) were observed for the full
12 months. Rivaroxaban treatment was prematurely
discontinued in 2,566 patients (23.1%), and data for
15 patients were missing. Of those patients in whom
rivaroxaban was prematurely ended, the documented
reason for treatment discontinuation was given by the
investigator as patient decision in 794 (7.1%) patients;
an AE in 724 patients (6.5%); a reason other than an AE
in 381 (3.4%) patients; and entering stable sinus
rhythm in 176 (1.6%) patients. The majority of patients
(n¼ 8,126 [73.1%]) initially received rivaroxaban 20mg
o.d., with 2,795 (25.1%), 179 (1.6%), and 18 (0.2%) pa-
tients initially receiving rivaroxaban 15 mg o.d.,
rivaroxaban 10 mg o.d., and other rivaroxaban doses
(30 mg, 25 mg, 7.5 mg, or 2.5 mg o.d.), respectively.
Dosing information was missing for 3 patients. Thereasons for initial dose selection were not recorded
during the study. Breakdown of dosing by region
(Figure 2) revealed that rivaroxaban 15 mg o.d. was
prescribed least often in Eastern Europe (14.8% of pa-
tients) and prescribedmost often in East Asia (44.4%of
patients), where local labeling recommendations
differ; in Taiwan (n ¼ 614), the approved rivaroxaban
dose for patients with CrCl >50 ml/min is 15 or 20 mg
o.d., and is 10 or 15 mg o.d. for patients with CrCl 15 to
50 ml/min (16). The approved doses of rivaroxaban in
other countries included in the study are 20mg o.d. for
patients with CrCl $50 ml/min and 15 mg o.d. for pa-
tients with CrCl 15 to 49 ml/min (17). The median
duration of treatment was 366 days (interquartile
range: 330 to 379 days), and the mean treatment
duration was 324.5  117.80 days.
Differences in patient demographics, clinical char-
acteristics, and stroke and bleeding risks were
apparent between study regions (Online Table 1). Pa-
tients enrolled from Western Europe/Canada/Israel,
East Asia, and Latin America were older, on average,
TABLE 2 Treatment-Emergent Thromboembolic and Bleeding Events, and All-Cause
Death in the Study Population
Incidence
Proportion
Incidence Rate
Events/100
Patient-Years
(95% CI)
All-cause death 187 (1.7) 1.9 (1.6–2.2)
Major bleeding 172 (1.5) 1.7 (1.5–2.0)
Fatal bleeding* 17 (0.2) 0.2 (0.1–0.3)
Critical organ bleeding 62 (0.6) 0.6 (0.5–0.8)
Intracranial hemorrhage 42 (0.4) 0.4 (0.3–0.6)
Intraparenchymal 12 (0.1) —
Subarachnoid 6 (0.1) —
Intraventricular 9 (0.1) —
Subdural hematoma 8 (0.1) —
Epidural hematoma 1 (<0.05) —
Hemorrhagic transformation of
ischemic stroke
6 (0.1) —
Missing 4 (<0.05) —
Mucosal bleeding 80 (0.7) 0.8 (0.6–1.0)
Gastrointestinal bleeding 71 (0.6) 0.7 (0.6–0.9)
Hemoglobin decrease $2 g/dl 58 (0.5) 0.6 (0.4–0.8)
Transfusion of $2 U of packed RBCs or
whole blood
73 (0.7) 0.7 (0.6–0.9)
Nonmajor bleeding events 1,195 (10.7) 12.8 (12.1–13.5)
Symptomatic thromboembolic events
(stroke, non-CNS SE, TIA, or MI)
179 (1.6) 1.8 (1.6–2.1)
Stroke/non-CNS SE 98 (0.9) 1.0 (0.8–1.2)
Stroke† 87 (0.8) 0.9 (0.7–1.1)
Primary hemorrhagic 20 (0.2) 0.2 (0.1–0.3)
Primary ischemic 64 (0.6) 0.6 (0.5–0.8)
Hemorrhagic transformation 6 (0.1) —
No hemorrhagic transformation 58 (0.5) —
Uncertain 6 (0.1) —
Non-CNS SE 11 (0.1) 0.1 (0.1–0.2)
TIA 41 (0.4) 0.4 (0.3–0.6)
MI 42 (0.4) 0.4 (0.3–0.6)
Any treatment-emergent AE 3,796 (34.1) 47.2 (45.7–48.8)
Any treatment-emergent serious AE 1,627 (14.6) 17.7 (16.8–18.5)
Values are n (%) unless otherwise indicated. *Fatal bleeding using narrow deﬁnitions (the patient experienced a
treatment-emergent major bleeding event and died within 30 days of the major bleeding event and the adju-
dicated primary cause of death was either intracranial hemorrhage or extracranial bleeding. †hemorrhagic strokes
and hemorrhagic transformations of ischemic stroke were adjudicated as both stroke and major bleeding. Mul-
tiple reasons for major bleedings were possible.
AE ¼ adverse event; RBC ¼ red blood cell; other abbreviations as in Table 1.
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147than patients enrolled in Eastern Europe and the
Middle East/Africa, whereas obesity (body mass index
>30 kg/m2) was more prevalent in patients from
Eastern Europe, the Middle East/Africa, and Latin
America compared with other regions. The highest
prevalence of hypertension, congestive heart failure,
and prior MI was reported in patients from Eastern
Europe, whereas patients from East Asia had the
highest prevalence of prior stroke/TIA/non-CNS SE.
Almost twice as many Middle Eastern/African patients
had diabetes mellitus versus other regions of the
world. The lowest stroke risk scores were found in
patients from Western Europe/Canada/Israel and the
Middle East/Africa; Middle Eastern/African and
Latin American patients had the lowest bleeding
risk scores.
OUTCOMES. Overall, the number of patients experi-
encing treatment-emergent major bleeding or throm-
boembolic events or death was low (Central
Illustration). More than 96% of patients did
not experience any of the outcomes of treatment-
emergent stroke/non-CNS SE, major bleeding, or all-
cause death.
There were 190 treatment-emergent major
bleeding events in 172 patients (1.7 events/100
patient-years) (Table 2). The incidence of fatal
bleeding was 0.2 events/100 patient-years; critical
organ bleeding occurred at a rate of 0.6 events/100
patient-years and included intracranial hemorrhage
(ICH) at a rate of 0.4 events/100 patient-years. The
most common site for major bleeding was the
gastrointestinal tract: 71 patients experienced major
gastrointestinal bleeding (0.7 events/100 patient-
years). Overall, 179 patients experienced 196 symp-
tomatic thromboembolic events (1.8 events/100
patient-years) (Table 2). These included 87 patients
with stroke (0.9 events/100 patient-years), 41 with
TIA (0.4 events/100 patient-years), 11 with systemic
embolic events (0.1 events/100 patient-years), and 42
with MI (0.4 events/100 patient-years). The incidence
of ischemic and hemorrhagic stroke was 0.6 and
0.2 events/100 patient-years, respectively. Rates of
major safety and effectiveness outcomes are sum-
marized in Figure 3.
The proportion of patients alive and free from
major bleeding or stroke/non-CNS SE was consistent
between regions (95.7% to 97.4%) (Online Figure 1,
Online Table 2). Although broadly similar, there were
subtle differences in the incidences of major out-
comes between regions. Major bleeding was higher in
Western Europe/Canada/Israel compared with the
range of rates observed in the other regions assessed
(2.3 vs. 0.7 to 1.6 events/100 patient-years), stroke/
non-CNS SE was highest in East Asia (1.8 vs. 0 to 1.0),and mortality was highest in the Middle East/Africa
and Latin America (2.7 vs. 1.5 to 2.0). The rates of
major bleeding, stroke/non-CNS SE, and all-cause
death were generally consistent between patients
with and without prior antithrombotic therapy across
regions (Online Figure 2, Online Table 3).
In total, 3,796 patients (34.1%) had a treatment-
emergent AE and 1,647 patients (14.6%) had a
treatment-emergent SAE. As expected, the incidence
of major bleeding and stroke/non-CNS SE increased
with age; the incidence rates of major bleeding in
patients <65, 65 to 75, and >75 years of age were 0.8,
1.4, and 2.9 events/100 patient-years, respectively.
FIGURE 3 Summary of the Key Effectiveness and Safety Outcomes in the XANTUS Pooled Analysis
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148The corresponding rates of stroke/non-CNS SE were
0.5, 1.1, and 1.2 events/100 patient-years, respec-
tively. Likewise, outcome analysis according to
CHADS2 and CHA2DS2-VASc scores showed that rates
of major bleeding, stroke/non-CNS SE, and all-cause
death tended to increase with increasing risk scores
(Figure 4).
CrCl values were reported in 7,072 patients (63.6%)
during the study; of these, 18.0% had CrCl <50 ml/min
and 82% had CrCl $50 ml/min. CrCl measurements
were available for more patients in Western Europe/
Canada/Israel and Eastern Europe than in the other
regions of the world (66.4% to 71.7% vs. 51.8% to
55.1%) (Online Table 1). Incidence rates for major
bleeding, all-cause death, and stroke/non-CNS SE
tended to increase with decreasing renal function;
rates tended to be lowest in patients with no available
CrCl data (Figure 5A). Rates (events/100 patient-years)
in patients with CrCl $15 to <30 ml/min versus
patients with CrCl >80 ml/min were major bleeding
6.1 versus 1.6; all-cause death 6.7 versus 1.3; and
stroke/non-CNS SE 1.5 versus 0.8.
According to the rivaroxaban label, dosing is
determined solely by renal function; in all countries
included in the XANTUS program, with the exception
of Taiwan, the label-recommended dose is rivarox-
aban 20 mg o.d. in patients with CrCl $50 ml/min and
15 mg o.d. in patients with CrCl 15 to 49 ml/min.
Analysis of rivaroxaban dosing by renal function
showed that, of 5,798 patients with a documented
CrCl $50 ml/min, 4,677 (80.7%) received the label-
recommended dose of rivaroxaban 20 mg o.d., 1,061
(18.3%) received rivaroxaban 15 mg o.d., and 58
(1.0%) received other nonrecommended doses. In
Taiwan, both rivaroxaban 15 mg o.d. and 20 mg o.d.are approved in patients with a CrCl >50 ml/min.
Thus, the 117 of the 1,061 patients with CrCl $50 ml/min
receiving rivaroxaban 15 mg o.d. from Taiwan likely
received a label-recommended dose.
Of the 1,227 patients with CrCl 15 to 49 ml/min,
467 (38.1%) received a nonrecommended dose of
rivaroxaban 20 mg o.d., 705 (57.5%) received the
recommended dose of rivaroxaban 15 mg o.d., and 55
(4.5%) received doses <15 mg o.d. In Taiwan, both
rivaroxaban 10 mg o.d. and 15 mg o.d. are approved
for use in patients with CrCl 15 to 50 ml/min, and
61 of the 190 patients who received rivaroxaban
doses <15 mg o.d. were Taiwanese; therefore, some of
the patients with CrCl 15 to 49 ml/min who received
rivaroxaban doses <15 mg o.d. were likely to have
been Taiwanese and dosed in accordance with their
local label. In total, 47 patients with CrCl <15 ml/min
received a nonrecommended dose of rivaroxaban.
Incidence rates for major bleeding, stroke/non-CNS
SE, and all-cause death tended to increase with
decreasing rivaroxaban dose (Figure 5B). Rates
(events/100 patient-years) in patients receiving
rivaroxaban 20 mg, 15 mg, or <15 mg o.d. were: major
bleeding 1.5, 2.3, and 4.6; all-cause death 1.4, 3.2, and
5.8; and stroke/non-CNS SE 0.8, 1.3, and 4.6,
respectively.
ADDITIONAL OUTCOMES. Overall, treatment persis-
tence at 1 year (deﬁned as patients who continued
treatment after their 1-year visit; patients who died
before 1 year were classiﬁed as nonpersistent) was
77.4%; between regions, persistence rates varied from
66.4% in East Asia to 76.2%–78.8% in the Middle
East/Africa, Latin America, and Western Europe/
Canada/Israel, and 84.4% in Eastern Europe. At the
ﬁnal visit, the majority of patients (72.9%) were either
FIGURE 4 Outcomes as a Function of CHADS2 and CHA2DS2-VASc Scores
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(A) CHADS2 and (B) CHA2DS2-VASc scores. There were 3 patients with missing CHA2DS2-VASc scores who did not experience any of the
outcomes of major bleeding, all-cause death, or stroke/non-CNS SE. *Composite of major bleeding, stroke/non-CNS SE, and all-cause death.
CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke or transient ischemic attack;
CHA2DS2–VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke, transient ischemic attack, or
thromboembolism, vascular disease, age 65–74 years, sex category (female); other abbreviations as in Figure 3.
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149“satisﬁed” or “very satisﬁed” with their treatment. A
further 16% of patients were “neutral,” 4.9% were
“unsatisﬁed,” and 1.3% were “very unsatisﬁed.” No
treatment satisfaction data were available for 4.9% of
patients.
In total, 914 treatment interruptions were reported
in 771 patients (6.9%); the median duration of treat-
ment interruption was 5 days (interquartile range: 2
to 13 days); heparin bridging therapy was used in137 (15%) interruptions. The most common reasons
for treatment interruption were bleeding in 236 pa-
tients (25.8%), surgery in 250 patients (27.4%), and
nonbleeding AEs in 161 patients (17.6%). Among pa-
tients with treatment interruption, major bleeding
and symptomatic thromboembolic events were re-
ported in 37 patients (4.8%) and 15 patients (1.9%),
respectively, during the interruption or until 2 days
after the interruption. If the event occurred on the
FIGURE 5 Outcomes as a Function of CrCl and Initial Rivaroxaban Dose
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150same date as the treatment interruption, however,
the possibility that the outcome event occurred
before the interruption cannot be excluded.
Rivaroxaban dose was changed at least once in 639
patients (5.7%); dose was changed only once in the
majority of these patients (n ¼ 567), with AEs being
the most common reason for a dose change. Dose
changes were more common in patients with
CrCl <50 ml/min (10.6%) than in those with a
CrCl $50 ml/min or unknown CrCl (5.1%). Major
bleeding events were mostly treated medically, and
nonspeciﬁc reversal agents were rarely used; of the
172 patients who experienced a major bleeding event,
use of tranexamic acid was documented in 5 patients,
blood coagulation factors in 3 patients, and the
hemostatic agent etamsylate in 2 patients.DISCUSSION
The entire XANTUS program, which analyzed data
from 11,121 patients worldwide, is the largest pro-
spective, observational, noninterventional study to
date of a single DOAC for stroke prevention in
patients with AF. The results from this pooled anal-
ysis showed that patients with AF throughout the
world had low rates of stroke and major bleeding in
the ﬁrst year after initiating rivaroxaban, and that
fatal and critical organ bleeding events, including
ICH, were rare, occurring in #0.6% of patients.
In the XANTUS global pooled analysis, incidence
rates of major outcomes, which were centrally adju-
dicated,were numerically lower than those reported in
rivaroxaban-treated patients from other real-world
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151studies. In 1,204 patients with AF treated with rivar-
oxaban in the prospective Dresden NOAC Registry, the
rates of major bleeding were 3.0 events/100 patient-
years compared with 1.7 events/100 patient-years
in the XANTUS program, whereas rates of thrombo-
embolic events were broadly similar (1.7 events/100
patient-years for stroke/TIA/SE in the XANTUS pro-
gram vs. 1.0 and 0.4 events/100 patient-years for
stroke/non-CNS SE and TIA in the Dresden NOAC
Registry, respectively) (18). In retrospective database
studies, similar differences in major bleeding rates
have been observed, with 2.84 events/100 patient-
years being reported in 44,793 U.S. (Department of
Defense) patients (vs. 1.7 events/100 patient-years in
the XANTUS program) (19). By contrast, ICH rates re-
ported from a large American retrospective database
analysis were similar to those in the XANTUS pooled
analysis, with 0.49%/year reported in 11,411 U.S. pa-
tients versus 0.4 events/100 patient-years in the
XANTUS pooled analysis (20,21). The numerically
lower rates of major bleeding reported in the XANTUS
program compared with these other studies are likely
to reﬂect differences in study design. A major strength
of the XANTUS pooled analysis is the adjudication of
outcome events by a central committee; this contrasts
with large claims database analyses, which have relied
on retrospective information coded in claims data-
bases to deﬁne events in the absence of adjudication.
Other factors that may account for the lower rates of
bleeding in the XANTUS program include possible self-
selection bias by patients for stroke and bleeding risk;
investigator bias during patient selection; major
bleeding deﬁnitions (ISTH major bleeding vs. major
bleeding identiﬁed from coding in patient databases);
differences in patient baseline characteristics and risk
proﬁles (e.g., differences in prior use of antith-
rombotics); as well as differences in the rivaroxaban
doses received (Online Table 4). The rates of major
bleeding, stroke/non-CNS SE and all-cause death were
generally similar between patients with and without
prior antithrombotic therapy (Online Figure 2, Online
Table 3). This suggested that the differences in event
rates observed between regions were unlikely to be
due to differences in prior antithrombotic therapy.
The label-recommended dose is similar in all coun-
tries (rivaroxaban 20 mg o.d. in patients with
CrCl $50 ml/min; rivaroxaban 15 mg o.d. in patients
with CrCl <50 ml/min) except Taiwan, where patients
with CrCl >50 ml/min can be prescribed either rivar-
oxaban 15 mg o.d. or 20 mg o.d., and 10 mg o.d. or 15 mg
o.d. can be prescribed in patients with CrCl 15 to 50 ml/
min. The majority of patients received rivaroxaban
doses in accordance with the label; over three-quarters
of patients with available CrCl measurements receivedthe recommended rivaroxaban dose in accordance with
their renal function. The ﬁnding that overall rates of
major outcomes increased with decreasing rivaroxaban
dose received suggests that patients with an on-label
recommendation to receive a reduced rivaroxaban
dose may be of poorer health and more prone to AEs
than patients who are label-recommended to receive
the standard rivaroxaban dose. Accordingly, rates of
major bleeding, all-cause death, and stroke/non-CNS SE
stratiﬁed by CrCl increased with decreasing CrCl. The
fact that just over one-ﬁfth of patients received rivar-
oxaban doses not aligned with their renal function and
that CrCl data were unavailable for more than one-third
of patients indicates a need for continued education of
physicians, with the aim of ensuring that rivaroxaban is
prescribed in accordance with the label. Nonetheless,
the fact that event rates for the major outcomes were
low in patients with unreported CrCl data suggests that
physicians are adept at identifying lower-risk patients
without assessment of CrCl. Another factor that could
have affected the results is the fact that the European
Society of Cardiology (ESC) guidelines on the manage-
ment of AF at the time of the XANTUS study recom-
mended a dose reduction in patients with a HAS-BLED
score $3 (22). Although this was not recommended by
the label, and has been changed in the current ESC
guidelines (22), it could account for the prescription of
rivaroxaban 15 mg o.d. in some patients without renal
impairment. This could be due to planned interventions
(e.g., cardioversion or ablation), other stroke risk factors
that are not captured in the CHA2DS2-VASc score, or
other reasons. The proportion of patients in the XAN-
TUS program receiving rivaroxaban with CHA2DS2-
VASc scores of 0 or 1 was comparable to that of other
reports, for example, the ORBIT AF (Outcomes Registry
for Better Informed Treatment of Atrial Fibrillation),
PREFER in AF (PREvention oF thromboembolic
events—European Registry in Atrial Fibrillation), EORP
(EURObservational Research Programme), or
GARFIELD-AF (Global Anticoagulant Registry in the
FIELD-Atrial Fibrillation) studies (23–25).
Subtle differences in patient baseline characteris-
tics and event rates were noted between regions in
the XANTUS program. The higher mortality in Middle
Eastern/African and Latin American patients, the
lower incidence of major bleeding in Eastern Euro-
pean and Latin American patients, and the higher
incidence of stroke/non-CNS SE in East Asian patients
(each vs. other regions) were broadly consistent with
the results of the RE-LY (Randomized Evaluation of
Long-Term Anticoagulation therapY) atrial ﬁbrillation
Registry and Cohort Study. This suggests regional
differences in baseline characteristics of patients may
account for differences in outcomes (26). In support
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152of this, the latter ﬁnding of a higher incidence of
stroke/non-CNS SE in patients of Asian origin cor-
roborates other ﬁndings identifying this patient
population as being at particularly high risk of stroke
(27,28). Patients from East Asia also had lower rates of
major bleeding than patients from Western Europe,
despite having a similar mean HAS-BLED (hyperten-
sion, abnormal renal or liver function, stroke,
bleeding, labile international normalized ratio,
elderly, drugs or alcohol) score; the reasons for these
differences are not fully understood. A major cause is
simply the higher proportion of patients from East
Asia receiving the 15-mg dose, but the ﬁndings are
also in keeping with the overall lower rates of major
bleeding observed in rivaroxaban-treated patients
from East Asia (29) and China (30) enrolled in the
ROCKET AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibitor Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation), relative to the ROCKET AF
population excluding these regions. By contrast, the
lower rates of major bleeding and ICH observed in the
XANTUS-EL study are consistent with a lower mean
HAS-BLED score in these patients than the respective
scores in both the XANTUS and XANAP studies.
Regional variations in treatment persistence were
also noted and broadly correlated with the differ-
ences in stroke/non-CNS SE event rates; the lowest
persistence (66.4%) was observed in patients from
East Asia, where the highest rate of stroke/non-CNS
SE was observed (1.8 events/100 patient-years),
whereas the highest persistence (84.4%) and lowest
rate of stroke/non-CNS SE (0.5 events/100 patient-
years) was observed in patients from Eastern
Europe. Up to 33.6% of patients discontinued treat-
ment, illustrating the need to develop care models
that ensure consistent delivery of evidence-based
therapy in different regions of the world.
Strengths of this analysis include the large sample
size: with 11,121 patients analyzed, this is the largest,
pre-planned, prospective pooling of studies of a DOAC
for stroke prevention in patients with AF to date,
identifying onlyminor regional variations in outcomes
in patients with AF treated with rivaroxaban. More-
over, the prospective nature of the studies, with
adjudicated endpoints, allows for greater complete-
ness of data and the potential for higher quality data
than retrospective designs. The independent endpoint
adjudication by the same committee for the entire
XANTUS program may have reduced reporting bias.
STUDY LIMITATIONS. Key limitations of the studies
included in the XANTUS program were the single-arm,
open-label design. As with any open-label study, thestudy design can introduce bias related to knowledge
about treatment. This was a global analysis, but pa-
tients from theUnited States or regions of China besides
Hong Kong were not included. Furthermore, interfer-
ence with patient management was not allowed
because of the noninterventional nature of the pro-
gram; this resulted in a relatively low number of pa-
tients with available renal function data, which limits
any implications these data may have. In addition,
because patients agreed to participate in the study, this
may have to some extent led to self-selection for risk of
stroke and bleeding. A selection bias around, for
example, intact cognitive function, could, therefore,
have arisenwith the investigator andmight have had an
impact on the low rates of stroke and bleeding.
CONCLUSIONS
The XANTUS program pooled is the largest prospec-
tive, observational analysis of a single DOAC used for
stroke prevention in patients with AF. This unique
pooled analysis, with central adjudication of out-
comes, combined data from 3 prospective, non-
interventional, multicenter analyses and enrolled
>11,000 patients from Western Europe, Israel,
Canada, Asia-Paciﬁc, Eastern Europe, the Middle East,
Africa, and Latin America. The results were consistent
across different regions and patient populations
worldwide, based on each of the individual rivarox-
aban studies, and further expand the body of evidence
on the safety of patients with AF receiving rivaroxaban
for stroke prevention. Overall, rivaroxaban showed a
favorable safety proﬁle, with >96% of the pooled
rivaroxaban population not experiencing any of the
events of treatment-emergent major bleeding, stroke/
non-CNS SE or all-cause death over a follow-up period
of approximately 1 year. Low rates of major bleeding
(includingmajor gastrointestinal bleeding) and stroke/
non-CNS SE were observed in these rivaroxaban-
treated patients in routine clinical practice.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE: In a pooled analysis
of several practice-based registries, patients with AF had
generally low rates of stroke, bleeding, and treatment
discontinuation and results were broadly consistent across
different regions of the world.
TRANSLATIONAL OUTLOOK: Additional research is
needed to understand the reasons that rivaroxaban and
other anticoagulant drugs are occasionally prescribed in
doses and clinical situations other than as recommended.
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